Rhumbline Advisers Blueprint Medicines Corp Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Rhumbline Advisers holds 86,531 shares of BPMC stock, worth $7.68 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
86,531
Previous 87,849 1.5%
Holding current value
$7.68 Million
Previous $8.12 Million 7.08%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
SELL
$82.48 - $101.39 $108,708 - $133,632
-1,318 Reduced 1.5%
86,531 $7.55 Million
Q3 2024

Nov 12, 2024
SELL
$84.1 - $120.5 $310,665 - $445,127
-3,694 Reduced 4.04%
87,849 $8.12 Million
Q2 2024

Aug 01, 2024
BUY
$85.18 - $108.78 $439,528 - $561,304
5,160 Added 5.97%
91,543 $9.87 Million
Q1 2024

May 09, 2024
BUY
$73.17 - $99.79 $147,583 - $201,276
2,017 Added 2.39%
86,383 $8.19 Million
Q4 2023

Feb 08, 2024
SELL
$43.96 - $92.84 $36,750 - $77,614
-836 Reduced 0.98%
84,366 $7.78 Million
Q3 2023

Nov 09, 2023
BUY
$46.9 - $66.0 $62,470 - $87,912
1,332 Added 1.59%
85,202 $4.28 Million
Q2 2023

Aug 08, 2023
BUY
$42.2 - $66.37 $111,281 - $175,017
2,637 Added 3.25%
83,870 $5.3 Million
Q1 2023

May 11, 2023
BUY
$37.97 - $50.0 $8,581 - $11,300
226 Added 0.28%
81,233 $3.66 Million
Q4 2022

Feb 14, 2023
BUY
$41.06 - $66.48 $67,872 - $109,891
1,653 Added 2.08%
81,007 $3.55 Million
Q3 2022

Nov 10, 2022
BUY
$49.93 - $77.7 $361,792 - $563,014
7,246 Added 10.05%
79,354 $5.23 Million
Q2 2022

Aug 11, 2022
BUY
$45.23 - $70.15 $392,325 - $608,481
8,674 Added 13.67%
72,108 $3.64 Million
Q1 2022

May 12, 2022
BUY
$54.1 - $110.08 $49,988 - $101,713
924 Added 1.48%
63,434 $4.05 Million
Q4 2021

Feb 10, 2022
SELL
$94.25 - $115.99 $126,954 - $156,238
-1,347 Reduced 2.11%
62,510 $6.7 Million
Q3 2021

Nov 12, 2021
BUY
$80.98 - $109.47 $95,556 - $129,174
1,180 Added 1.88%
63,857 $6.57 Million
Q2 2021

Aug 05, 2021
BUY
$82.78 - $101.0 $38,327 - $46,763
463 Added 0.74%
62,677 $5.51 Million
Q1 2021

May 06, 2021
SELL
$90.71 - $108.28 $695,564 - $830,291
-7,668 Reduced 10.97%
62,214 $6.05 Million
Q4 2020

Feb 10, 2021
BUY
$92.08 - $124.48 $174,675 - $236,138
1,897 Added 2.79%
69,882 $7.84 Million
Q3 2020

Nov 12, 2020
SELL
$66.45 - $92.7 $1.13 Million - $1.58 Million
-17,029 Reduced 20.03%
67,985 $6.3 Million
Q2 2020

Aug 13, 2020
BUY
$57.09 - $79.27 $514,038 - $713,747
9,004 Added 11.85%
85,014 $6.63 Million
Q1 2020

May 06, 2020
BUY
$48.11 - $82.22 $235,835 - $403,042
4,902 Added 6.89%
76,010 $4.45 Million
Q4 2019

Feb 05, 2020
BUY
$66.73 - $82.59 $204,060 - $252,560
3,058 Added 4.49%
71,108 $5.7 Million
Q3 2019

Oct 23, 2019
SELL
$72.9 - $101.41 $15,746 - $21,904
-216 Reduced 0.32%
68,050 $5 Million
Q2 2019

Aug 14, 2019
BUY
$73.54 - $97.8 $989,701 - $1.32 Million
13,458 Added 24.55%
68,266 $6.44 Million
Q1 2019

May 01, 2019
SELL
$48.7 - $86.6 $26,346 - $46,850
-541 Reduced 0.98%
54,808 $4.39 Million
Q4 2018

Jan 31, 2019
BUY
$45.57 - $74.26 $796,335 - $1.3 Million
17,475 Added 46.14%
55,349 $2.98 Million
Q3 2018

Nov 07, 2018
SELL
$58.91 - $78.32 $152,282 - $202,457
-2,585 Reduced 6.39%
37,874 $2.96 Million
Q2 2018

Aug 06, 2018
SELL
$60.96 - $101.18 $28,041 - $46,542
-460 Reduced 1.12%
40,459 $2.57 Million
Q1 2018

May 02, 2018
BUY
$73.28 - $102.95 $586 - $823
8 Added 0.02%
40,919 $3.75 Million
Q4 2017

Feb 09, 2018
SELL
$62.91 - $88.32 $259,315 - $364,055
-4,122 Reduced 9.15%
40,911 $3.09 Million
Q3 2017

Nov 06, 2017
BUY
$42.37 - $69.67 $1.91 Million - $3.14 Million
45,033
45,033 $3.14 Million

Others Institutions Holding BPMC

# of Institutions
379
Shares Held
61.6M
Call Options Held
1.6M
Put Options Held
1.41M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.3B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email